Patent US6096716A successfully refreshed from Google Patents.
US6096716A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liposome-mediated transfection of central nervous system cells
Assignee: The University of Texas System
•
Filing: 1994-12-12
•
Granted: 2000-08-01
•
Expires: 2014-12-12
Abstract
Abstract Disclosed are methods for use in transferring nucleic acids into central nervous system cells in vivo and in vitro and/or for stimulating central nervous system cells. Neurotrophic genes are shown to stimulate neurofilament cells and to promote nerve cell growth, repair and regeneration in vivo. Gene transfer protocols are disclosed for use in transferring various nucleic acid materials into central nervous system cells, as may be used in treating various pathologies of the brain and spinal cord.
Inventors
- 👤 Ronald L. Hayes
- 👤 Keyi Yang
- 👤 Fabrizia Faustinella
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 11:28
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/87; C12N15/88; A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K9/1272; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/48; A61K38/00
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
132 words
A method for treating nerve cells by transfection comprising the steps of: (a) selecting a nerve cell tissue site of an animal suffering a traumatic brain or spinal cord injury; (b) administering to the cells of said nerve tissue site of said animal by direct injection an effective amount of a composition comprising a nucleic acid segment encoding a neurotrophin, and a liposome comprising at least one cationic lipid; wherein said neurotropin is selected from the group consisting of nerve growth factor (NGF) and brain-derived nerve growth factor (BDNF), and wherein said cells of said nerve tissue site in said animal are transfected with said composition resulting in the transient expression of said neurotrophin in said cells causing a reduction of neuron death or cytoskeletal protein damage in said nerve tissue site.
Claim 2
Independent Claim
132 words
A method for treating nerve cells by transfection comprising the steps of: (a) selecting a nerve cell tissue site of an animal suffering a traumatic brain or spinal cord injury; (b) administering to the cells of said nerve tissue site of said animal by direct injection an effective amount of a composition comprising a nucleic acid segment encoding a neurotrophin, and a liposome comprising at least one cationic lipid; wherein said neurotropin is selected from the group consisting of nerve growth factor (NGF) and brain-derived nerve growth factor (BDNF), and wherein said cells of said nerve tissue site in said animal are transfected with said composition resulting in the transient expression of said neurotrophin in said cells causing a reduction of neuron death or cytoskeletal protein damage in said nerve tissue site.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein said animal is a human.
Claim 4
Dependent Claim
24 words
The method of claim 1, wherein the liposome further comprises a phospholipid and wherein the cationic lipid is DOTMA and the phospholipid is DOPE.
Claim 5
Dependent Claim
15 words
The method of claim 3, wherein DOTMA and DOPE are in about a 1:1 ratio.
Claim 6
Dependent Claim
23 words
The method of claim 1, wherein the nucleic acid segment and the liposome are in a ratio from about 1:1 to about 1:9.
Claim 7
Dependent Claim
11 words
The method of claim 5, wherein the ratio is about 1:3.
Claim 8
Dependent Claim
13 words
The method of claim 1, wherein the nucleic acid segment comprises a promoter.
Claim 9
Dependent Claim
12 words
The method of claim 7, wherein the promoter is CMV or RSV.
Claim 10
Dependent Claim
15 words
The method of claim 1, wherein the transient expression persists for at least a day.
Claim 11
Dependent Claim
15 words
The method of claim 1, wherein the transient expression persists for at least a week.
Claim 12
Dependent Claim
15 words
The method of claim 1, wherein the transient expression persists for at least two weeks.
Claim 13
Dependent Claim
25 words
The method of claim 1, wherein the direct injection is by syringe, an osmotic pump, a ventricular cannuli injection device or an intraparenchymal injection device.
Claim 14
Dependent Claim
13 words
The method of claim 1, wherein the cytoskeletal protein is a neurofilament protein.
Claim 15
Dependent Claim
22 words
The method of claim 13, wherein the neurofilament protein is a 200 kDa, a 150 kDa, or a 68 kDa neurofilament protein.
Claim 16
Independent Claim
132 words
A method for treating nerve cells by transfection comprising the steps of: (a) selecting a nerve cell tissue site of a human suffering a traumatic brain or spinal cord injury; (b) administering to the cells of said nerve tissue site of said human by direct injection an effective amount of a composition comprising a nucleic acid segment encoding a neurotrophin, and a liposome comprising at least one cationic lipid; wherein said neurotropin is selected from the group consisting of nerve growth factor (NGF) and brain-derived nerve growth factor (BDNF), and wherein said cells of said nerve tissue site in said human are transfected with said composition resulting in the transient expression of said neurotrophin in said cells causing a reduction of neuron death or cytoskeletal protein damage in said nerve tissue site.
Claim 17
Independent Claim
132 words
A method for treating nerve cells by transfection comprising the steps of: (a) selecting a nerve cell tissue site of a human suffering a traumatic brain or spinal cord injury; (b) administering to the cells of said nerve tissue site of said human by direct injection an effective amount of a composition comprising a nucleic acid segment encoding a neurotrophin, and a liposome comprising at least one cationic lipid; wherein said neurotropin is selected from the group consisting of nerve growth factor (NGF) and brain-derived nerve growth factor (BDNF), and wherein said cells of said nerve tissue site in said human are transfected with said composition resulting in the transient expression of said neurotrophin in said cells causing a reduction of neuron death or cytoskeletal protein damage in said nerve tissue site.
Claim 18
Dependent Claim
24 words
The method of claim 15 wherein the liposome further comprises a phospholipid and wherein the cationic lipid is DOTMA and the phospholipid is DOPE.
Claim 19
Dependent Claim
15 words
The method of claim 16, wherein DOTMA and DOPE are in about a 1:1 ratio.
Claim 20
Dependent Claim
23 words
The method of claim 17 wherein the nucleic acid segment and the liposome are in a ratio from about 1:1 to about 1:9.
Claim 21
Dependent Claim
11 words
The method of claim 18, wherein the ratio is about 1:3.
Claim 22
Dependent Claim
13 words
The method of claim 15, wherein the nucleic acid segment comprises a promoter.
Claim 23
Dependent Claim
12 words
The method of claim 20, wherein the promoter is CMV or RSV.
Claim 24
Dependent Claim
15 words
The method of claim 15, wherein the transient expression persists for at least a day.
Claim 25
Dependent Claim
15 words
The method of claim 15, wherein the transient expression persists for at least a week.
Claim 26
Dependent Claim
15 words
The method of claim 15, wherein the transient expression persists for at least two weeks.
Claim 27
Dependent Claim
25 words
The method of claim 15, wherein the direct injection is by syringe, an osmotic pump, a ventricular cannuli injection device or an intraparenchymal injection device.
Claim 28
Dependent Claim
13 words
The method of claim 15, wherein the cytoskeletal protein is a neurofilament protein.
Claim 29
Dependent Claim
22 words
The method of claim 26, wherein the neurofilament protein is a 200 kDa, a 150 kDa, or a 68 kDa neurofilament protein.
References Cited (Backward Citations)
WO1993008828A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-08-01 | 2004-01-31 | 2004-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-08-01 | 2008-01-31 | 2008-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-08-01 | 2012-01-31 | 2012-08-01 | $7700.00 | Window Closed / Lapsed |